# ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ANIP
## Company Profile
- Ticker: ANIP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Generics
## Stock Data
- Close: 74.53 USD
- Market cap: 1697139233.7 USD
- Last updated: 2026-08-11
## Business Overview
### Rare-Disease and Specialty Pharmaceuticals
ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines.
### Cortrophin Gel
Purified Cortrophin Gel is an adrenocorticotropic hormone therapy used across selected autoimmune and inflammatory indications. It is the primary growth driver of ANI's rare-disease franchise.
### Ophthalmology Portfolio
ILUVIEN and YUTIQ are sustained-release fluocinolone implants for retinal diseases, including diabetic macular edema and chronic noninfectious uveitis affecting the posterior segment.
## Why The Stock Is Moving

As of Aug 11, 2026, ANIP closed down 1.62% at $74.53. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 4 SYNCHRONICITY results in noninfectious uveitis at a medical conference in the third quarter of 2026.

## Recent News
- 2026-08-07 10:50 EST — [ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-record-second-quarter-2026-financial-results-68f15c4b) — Source: ANI Pharmaceuticals
- 2026-07-24 10:50 EST — [ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-august-7-f8a7cc57) — Source: ANI Pharmaceuticals
- 2026-07-16 20:34 EST — [ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-intent-to-appeal-rulings-in-cg-oncology-matter-62a30dad) — Source: ANI Pharmaceuticals
- 2026-07-13 10:50 EST — [ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-positive-six-month-topline-data-from-the-phase-4-o-658a24f6) — Source: ANI Pharmaceuticals
- 2026-05-27 10:50 EST — [ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conferenc-f9d25fa3) — Source: ANI Pharmaceuticals